These results revealed that, in the EC xenograft tumor model, treatment with oe-LINC00152 alone could induce greater drug resistance of EC cells, while the combination of oe-LINC00152 and si-ZEB1 increase the sensitivity of EC cells to L-OHP, thus reducing chemoresistance. This evidence concerns the gene ZEB1 and neoplasm.